IthaChrom

Ret. time (minutes)	From:	To:

Area (%)	From:	To:

ID	Hb Variant	Gene	Instrument	Method	Area (%)	Ret Time (min)	Comments
ID	Hb Variant	Gene	Instrument	Method			Comments
5	Hb I-Interlaken	α1	VARIANT II	Dual Kit Program	24.3	1.56	Heterozygous
9	HbS	β	VARIANT II	Dual Kit Program	33.7	3.47	Heterozygous / Sickle Cell Trait	[PDF]
17	HbC	β	VARIANT II	Dual Kit Program	82.3	4.42	Compound heterozygous with CD 39. Could be confused with HbC homozygous. A2 level and hematological data suggest an associated beta-thal.	[PDF]
38	HbE	β	VARIANT II	Dual Kit Program	27.6	3.65	Heterozygous	[PDF]
39	HbE	β	VARIANT II	Dual Kit Program	22.4	2.969	Heterozygous	[PDF]
44	Hb Shelby	β	VARIANT II	Dual Kit Program	73.6	4.74	Compound heterozygote between Hb Shelby and beta (0) Thal.	[PDF]
47	HbS	β	VARIANT II	Dual Kit Program	23.8	4.46	HbS heterozygote with alpha thalassaemia (HbS + alpha-thal 2).	[PDF]
48	HbS	β	VARIANT II	Dual Kit Program	21.3	3.49	HbS heterozygote with alpha thalassaemia (HbS + alpha-thal 2).	[PDF]
51	Hb Siirt	β	VARIANT II	Dual Kit Program	80.3	1.76	Heterozygote clinically normal, the mild thalassemic syndrome observed may be in relation with the associated alpha gene abnormality (triple alpha). Hb Siirt elutes together with HbA.	[PDF]
53	Hb G-Honolulu	α1	VARIANT II	Dual Kit Program	21.1	3.8	Heterozygous. Clinically normal. Hb G-Honolulu elutes together with HbA2.	[PDF]
54	Hb G-Honolulu	α1	VARIANT II	Dual Kit Program	20.2	3.18
57	Hb St. Claude	α1 or α2	VARIANT II	Dual Kit Program	22.1	1.49	Heterozygous. Clinically normal.	[PDF]
60	Hb G-Coushatta	β	VARIANT II	Dual Kit Program	61.1	2.69	Homozygous or associated with beta (0) thal.
63	Hb Camden	β	VARIANT II	Dual Kit Program	50.3	0.87	Clinically normal. Elutes near, or at the position of Hb A1c.	[PDF]
69	Hb Dhofar	β	VARIANT II	Dual Kit Program	18.9	3.12	Thalassemic Hb (in cis with a beta (+)-thalassemic mutation).	[PDF]
72	Hb Pierre-Bénite	β	VARIANT II	Dual Kit Program	83.2	1.753	This variant displays a high oxygen affinity and leads to erythrocytosis. Elutes as HbA0.	[PDF]
76	Hb Bicêtre	β	VARIANT II	Dual Kit Program	83.8	1.8	Unstable variant. Elutes with HbA.	[PDF]
80	Hb M-Saskatoon	β	VARIANT II	Dual Kit Program	4.4	4.51	Methemoglobinemia and unstable variant.	[PDF]
84	Hb Rainier	β	VARIANT II	Dual Kit Program	72.2	1.77	Increased oxygen affinity leading to erythrocytosis. Elutes as HbA.	[PDF]
88	Hb J-Baltimore	β	VARIANT II	Dual Kit Program	43.9	1.567	Clinically normal.	[PDF]
92	Hb Acharnes	β	VARIANT II	Dual Kit Program	80.1	1.776	Unstable variant. Chronic hemolytic anemia. Elutes together with HbA0 or as a shoulder in the ascending part.	[PDF]
96	Hb Chad	α2	VARIANT II	Dual Kit Program	20.6	4.115	Heterozygous. Clinically normal.	[PDF]
100	Hb Roanne	α1 or α2	VARIANT II	Dual Kit Program	87.9	1.76	Heterozygote clinically normal. Elutes as HbA.	[PDF]
108	Hb D-Ouled Rabah	β	VARIANT II	Dual Kit Program	59.2	2.736		[PDF]
113	Hb Lyon-Bron	α2	VARIANT II	Dual Kit Program	29.9	1.502	Heterozygous. Slightly decreased oxygen affinity, mild anaemia.	[PDF]
117	Hb Saint-Jacques	β	VARIANT II	Dual Kit Program	29.6	2.316	Heterozygous. Hb variant with increased oxygen affinity.	[PDF]
119	Hb Hamilton	β	VARIANT II	Dual Kit Program	86	1.789	Neutral variant, clinically normal. Elutes together with HbA on CE-HPLC. Abnormal chain could be observed by RP-HPLC. Diagnosis requires DNA studies.	[PDF]
123	Hb Gerland	α2	VARIANT II	Dual Kit Program	8.1	2.609	Heterozygous. Elutes with HbA. Clinically asymptomatic neutral alpha chain variant.	[PDF]
128	Hb Aubagne	β	VARIANT II	Dual Kit Program	85.6	1.801	Heterozygous. Unstable variant, mild hemolytic anaemia. Appears as a shoulder in the descending part of HbA0.	[PDF]
132	Hb Stanleyville-II	α2	VARIANT II	Dual Kit Program	32.1	3.401	Heterozygous. Clinically normal. Elutes as HbS.	[PDF]
136	Hb J-Sardegna	α2	VARIANT II	Dual Kit Program	25.4	0.676	Heterozygous. Elutes with HbF. DNA sequencing showed that the mutation leads to an Asn which is totally deamidated.	[PDF]
140	Hb Russ	α1	VARIANT II	Dual Kit Program	16	3.483	Heterozygous. Elutes in HbS window. Clinically normal.	[PDF]
144	Hb K Woolwich	β	VARIANT II	Dual Kit Program	37.2	0.859	Clinically and hematologically normal.	[PDF]
148	Hb Maputo	β	VARIANT II	Dual Kit Program	40.1	2.98	Clinically normal. Elutes as HbA2.	[PDF]
152	Hb Brem-sur-Mer	β	VARIANT II	Dual Kit Program	1.5	3.027	Clinically and hematologically normal. Elutes as HbA.	[PDF]
156	Hb Fannin-Lubbock II	β	VARIANT II	Dual Kit Program	36.5	1.66	This variant carries in addition to the mutation of Hb Fannin Lubbock [Gly>Asp] a second neutral mutation [beta Val>Leu] which modifies the retention time in RP-HPLC. Clinically normal.	[PDF]
164	Hb Malmö	β	VARIANT II	Dual Kit Program	46.2	1.427	High oxygen affinity variant, leads to erythrocytosis. Elutes together with HbA or before according to the chromatographic system used.	[PDF]
169	Hb Lombard	α2	VARIANT II	Dual Kit Program	87.9	1.809	Heterozygous. Elutes as a shoulder in the descending part of the HbA peak.	[PDF]
173	Hb J-Tongariki	α1 or α2	VARIANT II	Dual Kit Program	21.6	1.684	Heterozygous. Associated with alpha 3.7	[PDF]
177	Hb D-Iran	β	VARIANT II	Dual Kit Program	40.3	2.823	Carrier. Clinically normal. Elutes as HbA2 in CE-HPLC. Compound heterozygotes HbS/Hb D-Iran behave clinically as HbA/HbS.	[PDF]
181	Hb Yaounde	β	VARIANT II	Dual Kit Program	73.2	1.822	Clinically normal. Elutes as HbA.	[PDF]
185	Hb Dunn	α1 or α2	VARIANT II	Dual Kit Program	13.4	3.257	Heterozygote. Elutes in HbD window.	[PDF]
189	Hb J-Toronto	α1	VARIANT II	Dual Kit Program	20	1.693	Heterozygote. Clinically normal.	[PDF]
193	Hb Chicago	α2	VARIANT II	Dual Kit Program	82.3	1.767	Heterozygous. Elutes as HbA.	[PDF]
194	Hb Chicago	α2	VARIANT II	Dual Kit Program	82.3	1.767	Heterozygous. Elutes as HbA.	[PDF]
198	Hb Hikari	β	VARIANT II	Dual Kit Program	31.5	1.753	Clinically normal.	[PDF]
202	Hb G-Szuhu	β	VARIANT II	Dual Kit Program	3.2	3.017		[PDF]
206	Hb Ambroise Pare	α2	VARIANT II	Dual Kit Program	80.7	1.797	Heterozygous. Elutes with HbA.	[PDF]
210	Hb Groene Hart	α1	VARIANT II	Dual Kit Program	80	1.772	Mild non-deletional alpha thal variant. Migrates as HbA.	[PDF]
214	Hb Q-Thailand	α1	VARIANT II	Dual Kit Program	23.8	3.644	heterozygote	[PDF]
219	Hb Milledgeville	α2	VARIANT II	Dual Kit Program	84.1	1.82	Heterozygous. Increased oxygen affinity leading to a mild erythrocytosis.	[PDF]
223	Hb Nunobiki	α2	VARIANT II	Dual Kit Program	6	1.55	Heterozygous. Increased oxygen affinity leading to a mild erythrocytosis.	[PDF]
235	Hb Randwick	β	VARIANT II	Dual Kit Program	61.2	2.98	Double heterozygote (Hb Randwick with Beta thalassemia). It elutes in the position of HbA0 in all the systems except in the VARIANT II Dual Beta Thal program where it co-elutes with HbA2. Its association with a beta thal is extremely rare and explains both the anaemia and an increased HbF and HbA2 and if it is a beta 0 thal all the fraction eluting at the position of HbA0 is the variant.	[PDF]
240	HbS	β	VARIANT II	Dual Kit Program	86.6	3.44	Sickle cell disease. The trace amount of HbA remains from a blood transfusion.	[PDF]
244	HbS	β	VARIANT II	Dual Kit Program	68.9	3		[PDF]
245	HbS	β	VARIANT II	Dual Kit Program	68.9	3		[PDF]
246	HbS	β	VARIANT II	Dual Kit Program	68.9	3.45		[PDF]
250	HbS	β	VARIANT II	Dual Kit Program	24.1	3.49	HbS carrier with homozygous alpha + thalassemia.	[PDF]
253	HbS	β	VARIANT II	Dual Kit Program	77.9	3.48	Homozygous HbS with high HbA1c.	[PDF]
257	Hb G-Philadelphia	α2	VARIANT II	Dual Kit Program	28.9	3.35	Heterozygous. Eluates as HbS. Associated with alpha thal.	[PDF]
261	HbC	β	VARIANT II	Dual Kit Program	24.9	4.438	Hb AC + alpha thal. The presence of an alpha thalassemia reduces the level of HbC and increases the microcytosis.	[PDF]
264	HbS	β	VARIANT II	Dual Kit Program	73.7	3.387	Classical chromatogram of a SS patient, the high HbF level suggests that the patient may be heterozygote (or perhaps homozygote) for one of the haplotype stimulating HbF synthesis.	[PDF]
268	HbC	β	VARIANT II	Dual Kit Program	32.2	4.433	heterozygote	[PDF]
272	Hb D-Iran	β	VARIANT II	Dual Kit Program	39	2.71	Heterozygous. Elutes as HbA2 in CE-HPLC.	[PDF]
276	Hb Hasharon	α1	VARIANT II	Dual Kit Program	19.2	4.19	heterozygote	[PDF]
280	Hb Hopkins-II	α1	VARIANT II	Dual Kit Program	19.5	1.5	heterozygote	[PDF]
284	Hb J-Bangkok	β	VARIANT II	Dual Kit Program	32.3	1.66	heterozygote	[PDF]
288	Hb J-Broussais	α2	VARIANT II	Dual Kit Program	12.2	1.48	Heterozygote. Elutes near or with HbA1c.	[PDF]
292	Hb J-Paris-I	α1	VARIANT II	Dual Kit Program	25.5	1.59	heterozygote
296	Hb J-Paris-I	α2	VARIANT II	Dual Kit Program	35	0.55	Heterozygote. Elutes together with HbF.	[PDF]
300	Hb Le Lamentin	α2	VARIANT II	Dual Kit Program	25.5	1.41	heterozygote	[PDF]
304	Hb O-Arab	β	VARIANT II	Dual Kit Program	30.6	4.01	Heterozygote, clinically normal.	[PDF]
308	Hb O-Padova	α2	VARIANT II	Dual Kit Program	14.5	3.93	Heterozygote. Clinically normal.	[PDF]
312	Hb Q-India	α1	VARIANT II	Dual Kit Program	14.9	3.93	Heterozygote. Clinically normal.	[PDF]
316	HbS	β	VARIANT II	Dual Kit Program	33.3	3.47	HbS homozygote, transfused.	[PDF]
320	Hb D-Ibadan	β	VARIANT II	Dual Kit Program	35.8	3.17	Carrier. Clinically normal.	[PDF]
324	Hb Valletta	β	VARIANT II	Dual Kit Program	81.6	1.75	Heterozygous. Elutes with HbA. Clinically normal. This mutation is usually linked in cis to HbF Malta.	[PDF]
330	Hb St. Luke's	α1	VARIANT II	Dual Kit Program	8.8	3.68	Heterozygous.	[PDF]
334	Hb Sunshine Seth	α2	VARIANT II	Dual Kit Program	15.2	3.956	heterozygote	[PDF]
338	HbE	β	VARIANT II	Dual Kit Program	69.4	2.9	Homozygote.	[PDF]
342	Hb Tacoma	β	VARIANT II	Dual Kit Program	67.1	1.77	Heterozygote carriers are clinically normal.	[PDF]
346	Hb Old Dominion/Burton-upon-Trent (OD/BuT)	β	VARIANT II	Dual Kit Program	38.9	1.58	heterozygote	[PDF]
350	Hb Hopkins-II	α1	VARIANT II	Dual Kit Program	22.6	1.49	Heterozygote.	[PDF]
354	Hb G-Philadelphia	α2	VARIANT II	Dual Kit Program	23	3.37	Heterozygous. Elutes as HbS. Associated with alpha thal.	[PDF]
356	Hb J-Bangkok	β	VARIANT II	Dual Kit Program	26.4	1.7	Clinically normal. Rare but found worldwide.	[PDF]
360	Hb Q-Iran	α2	VARIANT II	Dual Kit Program	19.2	4.09	heterozygote	[PDF]
364	HbC	β	VARIANT II	Dual Kit Program	74.8	4.41	Homozygous.	[PDF]
368	Hb Le Lamentin	α2	VARIANT II	Dual Kit Program	29.1	1.47	heterozygote	[PDF]
372	Hb J-Meerut	α2	VARIANT II	Dual Kit Program	9.5	1.53	heterozygote	[PDF]
375	Hb Winnipeg	α1	VARIANT II	Dual Kit Program	16.1	4.084	Heterozygote.	[PDF]
379	Hb Seal Rock	α2	VARIANT II	Dual Kit Program	0.7	4.104	Heterozygous. Modified C-terminal sequence.	[PDF]
383	Hb D-Punjab	β	VARIANT II	Dual Kit Program	38.5	3.233	heterozygote	[PDF]
387	Hb G-Accra	β	VARIANT II	Dual Kit Program	43.1	3.144	Normal in the heterozygote.	[PDF]
391	Hb Hope	β	VARIANT II	Dual Kit Program	47.8	0.921	In neonatal screening this Hb may be masked by the large amount of HbF and a baby compound heterozygous for HbS and Hb Hope may erroneously appear as an HbS homozygote.	[PDF]
395	Hb Austin	β	VARIANT II	Dual Kit Program	44	1.592	Normal in the heterozygote.	[PDF]
399	HbS	β	VARIANT II	Dual Kit Program	27.1	3.487	HbS carrier with alpha thalassemia (homoz. alpha 3.7).	[PDF]
403	HbS	β	VARIANT II	Dual Kit Program	30.5	3.499	HbS + alpha-thal 2 (-3.7 del.).	[PDF]
408	Hb G-Copenhagen	β	VARIANT II	Dual Kit Program	38.8	2.896	Clinically normal. Elutes together with HbA2.	[PDF]
412	Hb G-San José	β	VARIANT II	Dual Kit Program	32.9	3.564	Clinically normal.	[PDF]
416	HbC	β	VARIANT II	Dual Kit Program	78.9	4.416	Homozygote.	[PDF]
420	Hb Santa Clara	β	VARIANT II	Dual Kit Program	45.6	1.522	Heterozygote.	[PDF]
424	Hb D-Punjab	β	VARIANT II	Dual Kit Program	30.6	3.276	Heterozygous. Clinically normal in heterozygotes. Mild anemia in homozygotes.	[PDF]
428	Hb Hasharon	α1	VARIANT II	Dual Kit Program	25.9	4.205	Heterozygote with alpha 3.7. Clinically normal in heterozygote.	[PDF]
432	Hb Hasharon	α1	VARIANT II	Dual Kit Program	27	4.207	Heterozygote with alpha 3.7. Clinically normal in heterozygote.	[PDF]
436	HbE	β	VARIANT II	Dual Kit Program	25.9	2.926	heterozygote	[PDF]
440	Hb Abruzzo	β	VARIANT II	Dual Kit Program	38.8	2.836	Hb with increased oxygen affinity.	[PDF]
444	Hb G-San José	β	VARIANT II	Dual Kit Program	31.3	3.623	Clinically normal.	[PDF]
448	Hb Roma	β	VARIANT II	Dual Kit Program	31.3	3.623	Elutes with HbA.	[PDF]
451	Hb Camperdown	β	VARIANT II	Dual Kit Program	45.5	0.958	Hb variant is mildly unstable.	[PDF]
455	Hb Randwick	β	VARIANT II	Dual Kit Program	2.9	2.995	Elutes with HbA2. Mildly unstable.	[PDF]
461	HbE	β	VARIANT II	Dual Kit Program	18.9	2.91	HbE heterozygote with alpha-thal 1 heterozygote.	[PDF]
465	HbE	β	VARIANT II	Dual Kit Program	27.2	2.899	Association of HbE and Hb Constant Spring	[PDF]
469	HbS	β	VARIANT II	Dual Kit Program	68.5	3.437	Heterozygote for Hb S/beta zero thal (Beta(0) CD39 (C/T)).	[PDF]
472	Hb Shelby	β	VARIANT II	Dual Kit Program	12.2	2.968	Compound heterozygous Hb Shelby / Beta zero Thalassemia.	[PDF]
476	Hb Shelby	β	VARIANT II	Dual Kit Program	3.9	2.979	heterozygote	[PDF]
480	Hb D-Punjab	β	VARIANT II	Dual Kit Program	75.4	3.191	Double heterozygote Hb D-Punjab and beta-thalassaemia.	[PDF]
485	Hb Valletta	β	VARIANT II	Dual Kit Program	61.2	1.886	Compound heterozygote with Hb Lepore. Elutes as HbA0.	[PDF]
487	Hb D-Punjab	β	VARIANT II	Dual Kit Program	84.8	3.212		[PDF]
498	HbS	β	VARIANT II	Dual Kit Program	38.6	3.472	Hb S/beta thal (probably a delta-beta thalassemia).	[PDF]
502	HbS	β	VARIANT II	Dual Kit Program	6.9	3.545	Newborn homozygous for HbS. The peak eluting at the position of HbA2 may be aged HbS.	[PDF]
506	HbS	β	VARIANT II	Dual Kit Program	53.6	3.465	HbS homozygous with HPFH.	[PDF]
512	HbS	β	VARIANT II	Dual Kit Program	45.7	3.427	Compound heterozygote for HbS and HbC	[PDF]
513	HbC	β	VARIANT II	Dual Kit Program	42.7	4.422	Compound heterozygote for HbC and HbS	[PDF]
516	HbS	β	VARIANT II	Dual Kit Program	70.6	3.402	Compound heterozygote for HbS and Beta (+) thal.	[PDF]
521	HbS	β	VARIANT II	Dual Kit Program	46.7	3.429	Compound heterozygote for HbS and HbC	[PDF]
522	HbC	β	VARIANT II	Dual Kit Program	43.2	4.431	Compound heterozygote for HbS and HbC.	[PDF]
526	HbS	β	VARIANT II	Dual Kit Program	59.5	3.432	Compound heterozygote for HbS and B (+) thalassaemia.	[PDF]
533	HbS	β	VARIANT II	Dual Kit Program	44.6	3.44	Compound heterozygote for HbS and HbC.	[PDF]
534	HbC	β	VARIANT II	Dual Kit Program	40.8	4.423	Compound heterozygote for HbS and HbC	[PDF]
540	Hb D-Punjab	β	VARIANT II	Dual Kit Program	40	3.21	Compound heterozygote for HbS and Hb D-Punjab	[PDF]
541	HbS	β	VARIANT II	Dual Kit Program	37.5	3.455	Compound heterozygote for HbS and Hb D-Punjab.	[PDF]
545	HbC	β	VARIANT II	Dual Kit Program	50	4.414	Compound heterozygote for HbC and (delta-beta) zero thalassaemia.	[PDF]
549	HbC	β	VARIANT II	Dual Kit Program	59.3	4.422	Compound heterozygote for HbC and beta-thalassaemia.	[PDF]
551	Hb Gouda	α2	VARIANT II	Dual Kit Program	33.3	1.557	heterozygote	[PDF]
555	Hb A2' or Hb B2	δ	VARIANT II	Dual Kit Program	0.8	3.62	Homozygous.	[PDF]
558	Hb N-Baltimore	β	VARIANT II	Dual Kit Program	79	1.535	Hb N-Baltimore / Beta zero thalassaemia. Clinical normal.	[PDF]
562	HbS	β	VARIANT II	Dual Kit Program	31.1	3.452	HbS carrier + alpha-thal 2 (-3.7 deletion).	[PDF]
567	HbE	β	VARIANT II	Dual Kit Program	42.6	2.885	Association of HbE and beta-thalassaemia.	[PDF]
574	HbC	β	VARIANT II	Dual Kit Program	43.8	4.419	Compound heterozygosity for HbC and Hb O Arab.	[PDF]
575	Hb O-Arab	β	VARIANT II	Dual Kit Program	42.1	3.999	Compound heterozygosity for HbC and Hb O Arab (extremely rare). This situation is important to be identified for genetic counselling since both alleles when associated to HbS lead to a severe sickle cell syndrome.	[PDF]
580	Hb Mexico	α1	VARIANT II	Dual Kit Program	28.1	1.49	Heterozygous.	[PDF]
584	HbI	α1	VARIANT II	Dual Kit Program	22.5	1.467	heterozygote	[PDF]
588	Hb Lepore-Boston-Washington	δ	VARIANT II	Dual Kit Program	13.1	2.827	Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.	[PDF]
588	Hb Lepore-Boston-Washington	β	VARIANT II	Dual Kit Program	13.1	2.827	Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.	[PDF]
592	Hb M-Milwaukee-2	β	VARIANT II	Dual Kit Program	31.1	4.435	Congenital methemoglobinemia.	[PDF]
596	Hb Lepore-Boston-Washington	δ	VARIANT II	Dual Kit Program	10.8	2.887	Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.	[PDF]
596	Hb Lepore-Boston-Washington	β	VARIANT II	Dual Kit Program	10.8	2.887	Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.	[PDF]
598	HbI	α1	VARIANT II	Dual Kit Program	27.9	1.491	Heterozygote.	[PDF]
602	Hb Aichi	α1 or α2	VARIANT II	Dual Kit Program	22.5	3.465	Heterozygous. Elutes as HbS.	[PDF]
605	Hb Setif	α2	VARIANT II	Dual Kit Program	6	1.529	Heterozygote. Elutes with HbA.	[PDF]
611	Hb Setif	α2	VARIANT II	Dual Kit Program	10.4	3.908	Heterozygote.	[PDF]
614	HbS	β	VARIANT II	Dual Kit Program	28.8	3.489	HbS carrier with Hb Montgomery (alpha variant).	[PDF]
615	Hb Montgomery	α2	VARIANT II	Dual Kit Program	6.5	4.425	Heterozygous. Association with HbS.	[PDF]
3	Hb I-Interlaken	α1	D-10	Dual Kit Program	24.5	1.45	Heterozygous	[PDF]
6	HbS	β	D-10	Dual Kit Program	34.2	4.06	Heterozygous / Sickle Cell Trait	[PDF]
14	HbC	β	D-10	Dual Kit Program	82.5	4.82	Compound heterozygous with CD 39. Could be confused with HbC homozygous. A2 level and hematological data suggest an associated beta-thal.	[PDF]
26	HbE	β	D-10	Dual Kit Program	28.9	3.15	Heterozygous	[PDF]
27	HbS	β	D-10	Dual Kit Program	52.7	4.04	Compound heterozygote between HbS and HPFH	[PDF]
45	HbS	β	D-10	Dual Kit Program	21.3	4.11	HbS heterozygote with alpha thalassaemia (HbS + alpha-thal 2).	[PDF]
49	Hb Siirt	β	D-10	Dual Kit Program	80.5	1.69	Heterozygote clinically normal, the mild thalassemic syndrome observed may be in relation with the associated alpha gene abnormality (triple alpha). Hb Siirt elutes together with HbA.	[PDF]
52	Hb G-Honolulu	α1	D-10	Dual Kit Program	19.4	3.83	Heterozygous. Clinically normal.	[PDF]
55	Hb St. Claude	α1 or α2	D-10	Dual Kit Program	21.8	1.42	Heterozygous. Clinically normal.	[PDF]
58	Hb G-Coushatta	β	D-10	Dual Kit Program	35	2.7	Homozygous or associated with beta (0) thal.	[PDF]
61	Hb Camden	β	D-10	Dual Kit Program	50.1	0.75	Clinically normal. Elutes near, or at the position of Hb A1c.	[PDF]
65	Hb Dhofar	β	D-10	Dual Kit Program	23.5	3.43	Thalassemic Hb (in cis with a beta (+)-thalassemic mutation).	[PDF]
70	Hb Pierre-Bénite	β	D-10	Dual Kit Program	83.3	1.66	This variant displays a high oxygen affinity and leads to erythrocytosis. Elutes as HbA0.	[PDF]
73	Hb Bicêtre	β	D-10	Dual Kit Program	83.4	1.69	Unstable variant. Elutes with HbA.	[PDF]
77	Hb M-Saskatoon	β	D-10	Dual Kit Program	6.9	4.7	Methemoglobinemia and unstable variant.	[PDF]
81	Hb Rainier	β	D-10	Dual Kit Program	73.2	1.69	Increased oxygen affinity leading to erythrocytosis. Elutes as a shoulder in the descending part of HbA.	[PDF]
85	Hb J-Baltimore	β	D-10	Dual Kit Program	42.9	1.52	Clinically normal.	[PDF]
89	Hb Acharnes	β	D-10	Dual Kit Program	81.7	1.7	Unstable variant. Chronic hemolytic anemia. Elutes together with HbA0 or as a shoulder in the ascending part.	[PDF]
93	Hb Chad	α2	D-10	Dual Kit Program	22.5	4.49	Heterozygous. Clinically normal.	[PDF]
97	Hb Roanne	α1 or α2	D-10	Dual Kit Program	87	1.7	Heterozygote clinically normal. Elutes as HbA.	[PDF]
101	Hb Providence	β	D-10	Dual Kit Program	16.4	0.97	This variant is spontaneously deaminated X-Asn 13-19%; X-Asp 32-33% leading to several fast eluting peaks.	[PDF]
102	Hb Toulon	α2	D-10	Dual Kit Program	33.5	2.96	Heterozygote clinically normal. Elutes in the HbA2 window.	[PDF]
105	Hb D-Ouled Rabah	β	D-10	Dual Kit Program	48.3	2.64	Carrier. Clinically normal. Elutes as HbA2 in CE-HPLC.	[PDF]
109	Hb Lyon-Bron	α2	D-10	Dual Kit Program	28.7	1.42	Heterozygous. Slightly decreased oxygen affinity, mild anaemia.	[PDF]
114	Hb Saint-Jacques	β	D-10	Dual Kit Program	76.1	1.72	Heterozygous. Hb variant with increased oxygen affinity.	[PDF]
120	Hb Gerland	α2	D-10	Dual Kit Program	87.4	1.68	Heterozygous. Elutes with HbA. Clinically asymptomatic neutral alpha chain variant.	[PDF]
125	Hb Aubagne	β	D-10	Dual Kit Program	82.7	1.69	Heterozygous. Unstable variant, mild hemolytic anaemia. Appears as a shoulder in the descending part of HbA0.	[PDF]
129	Hb Stanleyville-II	α2	D-10	Dual Kit Program	31.2	4.01	Heterozygous. Clinically normal.	[PDF]
133	Hb J-Sardegna	α2	D-10	Dual Kit Program	30	0.51	Heterozygous. Elutes with HbF. DNA sequencing showed that the mutation leads to an Asn which is totally deamidated.	[PDF]
137	Hb Russ	α1	D-10	Dual Kit Program	15.3	4.09	Heterozygous. Elutes in HbS window. Clinically normal.	[PDF]
141	Hb K Woolwich	β	D-10	Dual Kit Program	33.5	0.65
145	Hb Maputo	β	D-10	Dual Kit Program	55	3.05	Clinically normal. Elutes as HbA2.	[PDF]
149	Hb Brem-sur-Mer	β	D-10	Dual Kit Program	72	1.72	Clinically and hematologically normal. Elutes as HbA.	[PDF]
153	Hb Fannin-Lubbock II	β	D-10	Dual Kit Program	34	1.54	This variant carries in addition to the mutation of Hb Fannin Lubbock [Gly>Asp] a second neutral mutation [beta Val>Leu] which modifies the retention time in RP-HPLC. Clinically normal.	[PDF]
157	Hb Passy	α2	D-10	Dual Kit Program	74.7	1.68	Heterozygous. Unstable variant.	[PDF]
159	Hb Handsworth	α1	D-10	Dual Kit Program	14.9	4.17	Heterozygous. Clinically normal.	[PDF]
161	Hb Shimonoseki	α1	D-10	Dual Kit Program	14.7	4.17	Heterozygous. Elutes as HbS.	[PDF]
165	Hb Lombard	α2	D-10	Dual Kit Program	0.5	2.55	Heterozygous. Elutes as a shoulder in the descending part of the HbA peak.	[PDF]
170	Hb J-Tongariki	α1 or α2	D-10	Dual Kit Program	20.3	1.59	Heterozygous. Associated with alpha 3.7.	[PDF]
174	Hb D-Iran	β	D-10	Dual Kit Program	45	2.64	Carrier. Clinically normal. Elutes as HbA2 in CE-HPLC. Compound heterozygotes HbS/Hb D-Iran behave clinically as HbA/HbS.	[PDF]
178	Hb Yaounde	β	D-10	Dual Kit Program	73	1.72	Clinically normal. Elutes as HbA.	[PDF]
182	Hb Dunn	α1 or α2	D-10	Dual Kit Program	14.4	3.8	Heterozygote. Elutes in Hb D window.	[PDF]
186	Hb J-Toronto	α1	D-10	Dual Kit Program	17.9	1.58	Heterozygote. Clinically normal.	[PDF]
190	Hb Chicago	α2	D-10	Dual Kit Program	82.3	1.69	Heterozygous. Elutes as HbA.	[PDF]
195	Hb Hikari	β	D-10	Dual Kit Program	73.7	1.72	Clinically normal. Elutes in HbA window.	[PDF]
199	Hb G-Szuhu	β	D-10	Dual Kit Program	32.2	4.17	Clinically normal. Elutes in HbS window.	[PDF]
203	Hb Ambroise Pare	α2	D-10	Dual Kit Program	79.7	1.67	Heterozygous. Elutes with HbA.	[PDF]
207	Hb Groene Hart	α1	D-10	Dual Kit Program	79.6	1.68	Mild non-deletional alpha thal variant. Migrates as HbA.	[PDF]
211	Hb Q-Thailand	α1	D-10	Dual Kit Program	22.5	4.18	heterozygote	[PDF]
216	Hb Milledgeville	α2	D-10	Dual Kit Program	5.8	1.44	Heterozygous. Increased oxygen affinity leading to a mild erythrocytosis.	[PDF]
220	Hb Nunobiki	α2	D-10	Dual Kit Program	5.8	1.44	Heterozygous. Increased oxygen affinity leading to a mild erythrocytosis.	[PDF]
224	Hb Summer Hill	β	D-10	Dual Kit Program	35.8	3.88	Heterozygote. Clinically normal. Elutes in HbS window.	[PDF]
226	Hb Fort de France	α1	D-10	Dual Kit Program	64.1	1.66	Heterozygote. Elutes in the window of HbA2.	[PDF]
228	Hb J-Broussais	α2	D-10	Dual Kit Program	14	1.12	Heterozygote. Elutes near or with HbA1c. Clinically normal.	[PDF]
230	HbS	β	D-10	Dual Kit Program	83.3	4.02	Homozygote. Classical chromatogram of an SS patient.	[PDF]
232	Hb Fort de France	α1	D-10	Dual Kit Program	16.1	3.06	Compound heterozygote. In this case HbA0 is a result of transfusion.	[PDF]
233	Hb K-Ibadan	β	D-10	Dual Kit Program	7.8	1.38	Heterozygote. Clinically normal.	[PDF]
236	HbS	β	D-10	Dual Kit Program	88.5	4.04	Homozygous Hb S. The trace amount of HbA remains from a blood transfusion.	[PDF]
241	HbS	β	D-10	Dual Kit Program	70.3	4.04	Homozygous HbS recently transfused.	[PDF]
247	HbS	β	D-10	Dual Kit Program	23.3	4.1	HbS carrier with homozygous alpha + thalassemia.	[PDF]
251	HbS	β	D-10	Dual Kit Program	74.1	4.07		[PDF]
254	Hb G-Philadelphia	α2	D-10	Dual Kit Program	30	3.92	Heterozygous. Associated with alpha thal.	[PDF]
258	HbC	β	D-10	Dual Kit Program	26	4.7	Hb AC + alpha thal. The presence of an alpha thalassemia reduces the level of HbC and increases the microcytosis.	[PDF]
262	HbS	β	D-10	Dual Kit Program	74.8	4.04	Classical chromatogram of a SS patient, the high HbF level suggests that the patient may be heterozygote (or perhaps homozygote) for one of the haplotype stimulating HbF synthesis.	[PDF]
265	HbC	β	D-10	Dual Kit Program	32.3	4.7	heterozygote	[PDF]
269	Hb D-Iran	β	D-10	Dual Kit Program	14.3	2.59	heterozygote	[PDF]
273	Hb Hasharon	α1	D-10	Dual Kit Program	21.5	4.53	heterozygote	[PDF]
277	Hb Hopkins-II	α1	D-10	Dual Kit Program	18.3	1.41	heterozygote	[PDF]
281	Hb J-Bangkok	β	D-10	Dual Kit Program	39.8	1.68	heterozygote	[PDF]
285	Hb J-Broussais	α2	D-10	Dual Kit Program	31.1	0.96	Heterozygote. Elutes with HbA1c.	[PDF]
289	Hb J-Paris-I	α1	D-10	Dual Kit Program	25.5	1.5	heterozygote	[PDF]
293	Hb J-Sardegna	α2	D-10	Dual Kit Program	36.1	0.46	Heterozygote. Elutes together with HbF.	[PDF]
297	Hb Le Lamentin	α2	D-10	Dual Kit Program	24.8	1.36	heterozygote	[PDF]
301	Hb O-Arab	β	D-10	Dual Kit Program	29.4	4.57	Heterozygote, clinically normal.	[PDF]
305	Hb O-Padova	α2	D-10	Dual Kit Program	14.2	4.42	Heterozygote, clinically normal.	[PDF]
309	Hb Q-India	α1	D-10	Dual Kit Program	14.8	4.37	Heterozygote. Clinically normal.	[PDF]
313	HbS	β	D-10	Dual Kit Program	32.4	4.08	Homozygous HbS recently transfused (Exchange transfused)	[PDF]
317	Hb D-Ibadan	β	D-10	Dual Kit Program	34.1	3.51	Carrier. Clinically normal.	[PDF]
321	Hb Valletta	β	D-10	Dual Kit Program	84.1	1.69	Heterozygous. Elutes with HbA. Clinically normal. This mutation is usually linked in cis to HbF Malta.	[PDF]
327	Hb St. Luke's	α1	D-10	Dual Kit Program	8.5	4.21	Heterozygous. Elutes with HbS.	[PDF]
331	Hb Sunshine Seth	α2	D-10	Dual Kit Program	14.8	4.43	heterozygote	[PDF]
335	HbE	β	D-10	Dual Kit Program	87.3	2.87	Homozygote.	[PDF]
339	Hb Tacoma	β	D-10	Dual Kit Program	67.5	1.7		[PDF]
343	Hb Old Dominion/Burton-upon-Trent (OD/BuT)	β	D-10	Dual Kit Program	36.3	1.52	heterozygote	[PDF]
347	Hb Hopkins-II	α1	D-10	Dual Kit Program	21.4	1.39	Heterozygote.	[PDF]
351	Hb G-Philadelphia	α2	D-10	Dual Kit Program	22.5	3.96	Heterozygous. Associated with alpha thal.	[PDF]
357	Hb Gouda	α2	D-10	Dual Kit Program	28.7	1.43	Heterozygote. Clinically normal.	[PDF]
361	HbC	β	D-10	Dual Kit Program	75.5	4.69	HbC homozygous or compound heterozygous with beta zero thalassaemia.	[PDF]
365	Hb Le Lamentin	α2	D-10	Dual Kit Program	28.8	1.38	heterozygote	[PDF]
369	Hb J-Meerut	α2	D-10	Dual Kit Program	9.1	1.42	heterozygote	[PDF]
373	Hb Winnipeg	α1	D-10	Dual Kit Program	16.7	4.46	Heterozygote.	[PDF]
376	Hb Seal Rock	α2	D-10	Dual Kit Program	1.5	4.59	Heterozygous. Modified C-terminal sequence.	[PDF]
380	Hb D-Punjab	β	D-10	Dual Kit Program	38.1	3.78	heterozygote	[PDF]
384	Hb G-Accra	β	D-10	Dual Kit Program	40.6	3.53	Normal in the heterozygote.	[PDF]
388	Hb Hope	β	D-10	Dual Kit Program	49.2	0.73	In neonatal screening this Hb may be masked by the large amount of HbF and a baby compound heterozygous for HbS and Hb Hope may erroneously appear as an HbS homozygote.	[PDF]
392	Hb Austin	β	D-10	Dual Kit Program	43.8	1.47	Normal in the heterozygote.	[PDF]
396	HbS	β	D-10	Dual Kit Program	26.4	4.09	HbS carrier with alpha thalassemia (homoz. alpha 3.7).	[PDF]
400	HbS	β	D-10	Dual Kit Program	30	4.09	HbS carrier + alpha-thal 2 (-3.7 del.).	[PDF]
405	Hb G-Copenhagen	β	D-10	Dual Kit Program	44.6	2.91	Clinically normal. Elutes together with HbA2.	[PDF]
409	Hb G-San José	β	D-10	Dual Kit Program	31	4.17	Clinically normal. Elutes in S Window.	[PDF]
413	HbC	β	D-10	Dual Kit Program	79.3	4.69	Homozygote.	[PDF]
417	Hb Santa Clara	β	D-10	Dual Kit Program	45.3	1.43	Heterozygote.	[PDF]
421	Hb D-Punjab	β	D-10	Dual Kit Program	29	3.81	Heterozygous. Clinically normal in heterozygotes. Mild anemia in homozygotes.	[PDF]
425	Hb Hasharon	α1	D-10	Dual Kit Program	25.4	4.56	Heterozygote with alpha 3.7. Clinically normal in heterozygote.	[PDF]
429	Hb Hasharon	α1	D-10	Dual Kit Program	29.1	4.56	Heterozygote with alpha 3.7. Clinically normal in heterozygote.	[PDF]
433	HbE	β	D-10	Dual Kit Program	29.6	2.96	heterozygote	[PDF]
438	Hb Abruzzo	β	D-10	Dual Kit Program	46.1	2.72	Hb with increased oxygen affinity.	[PDF]
441	Hb G-San José	β	D-10	Dual Kit Program	28.5	4.18	Clinically normal. Elutes in S Window.	[PDF]
445	Hb Roma	β	D-10	Dual Kit Program	28.5	4.18	Elutes with HbA.	[PDF]
452	Hb Randwick	β	D-10	Dual Kit Program	81.4	1.69	Elutes with HbA. Mildly unstable.	[PDF]
458	HbE	β	D-10	Dual Kit Program	19.9	2.96	HbE heterozygote with alpha-thal 1 heterozygote.	[PDF]
462	HbE	β	D-10	Dual Kit Program	28.8	2.92	Association of HbE and Hb Constant Spring	[PDF]
467	HbS	β	D-10	Dual Kit Program	67.9	4.03	Heterozygote for Hb S/beta zero thal (Beta(0) CD39 (C/T))	[PDF]
470	Hb Shelby	β	D-10	Dual Kit Program	11.7	3.06	Compound heterozygous Hb Shelby / Beta zero Thalassemia.	[PDF]
473	Hb Shelby	β	D-10	Dual Kit Program	5.8	3.1	heterozygote	[PDF]
477	Hb D-Punjab	β	D-10	Dual Kit Program	70.8	3.7	Double heterozygote Hb D-Punjab and beta-thalassaemia.	[PDF]
482	Hb Valletta	β	D-10	Dual Kit Program	66.3	1.74	Compound heterozygote with Hb Lepore. Elutes as HbA0.	[PDF]
486	Hb D-Punjab	β	D-10	Dual Kit Program	81	3.74		[PDF]
488	HbC	β	D-10	Dual Kit Program	29.6	4.7	compounnd heterozygote for HbC and Hb Korle Bu	[PDF]
490	HbS	β	D-10	Dual Kit Program	31.4	4.07	Compound heterozygote for HbC and HbS	[PDF]
493	Hb Randwick	β	D-10	Dual Kit Program	52.4	1.82	Double heterozygote for Hb Randwick and beta-thalassaemia.	[PDF]
496	HbS	β	D-10	Dual Kit Program	39.5	4.22	Hb S/beta thal (probably a delta-beta thalassemia).	[PDF]
499	HbS	β	D-10	Dual Kit Program	8	4.12	Newborn homozygous for HbS. The peak eluting at the position of HbA2 may be aged HbS.	[PDF]
503	HbS	β	D-10	Dual Kit Program	54.4	4.07	HbS homozygous with HPFH.	[PDF]
508	HbS	β	D-10	Dual Kit Program	46	4.08	Compound heterozygote for HbS and HbC, together with alpha-thal 2.	[PDF]
509	HbC	β	D-10	Dual Kit Program	46.4	4.7	Compound heterozygote for HbS and HbC	[PDF]
514	HbS	β	D-10	Dual Kit Program	69.2	4.05	Compound heterozygote for HbS and Beta (+) thal	[PDF]
517	HbS	β	D-10	Dual Kit Program	46.1	4.06	Compound heterozygote for HbS and HbC	[PDF]
518	HbC	β	D-10	Dual Kit Program	46.3	4.7	Compound heterozygote for HbS and HbC	[PDF]
520	HbC	β	D-10	Dual Kit Program	46.3	5.12	Compound heterozygote for HbS and HbC	[PDF]
523	HbS	β	D-10	Dual Kit Program	58.9	4.06	Compound heterozygote for HbS and B (+) thalassaemia.	[PDF]
527	HbS	β	D-10	Dual Kit Program	44.4	4.07	Compound heterozygote for HbS and HbC	[PDF]
528	HbC	β	D-10	Dual Kit Program	43.6	4.71	Compound heterozygote for HbS and HbC	[PDF]
535	Hb D-Punjab	β	D-10	Dual Kit Program	37.9	3.74	Compound heterozygote for HbS and Hb D-Punjab	[PDF]
542	HbC	β	D-10	Dual Kit Program	50.4	4.7	Compound heterozygote for HbC and (delta-beta) zero thalassaemia.	[PDF]
546	HbC	β	D-10	Dual Kit Program	59.4	4.7	heterozygote	[PDF]
552	Hb A2' or Hb B2	δ	D-10	Dual Kit Program	1.5	4.19		[PDF]
556	Hb N-Baltimore	β	D-10	Dual Kit Program	80.8	1.46	Hb N-Baltimore / Beta zero thalassaemia. Clinical normal.	[PDF]
559	HbS	β	D-10	Dual Kit Program	30.7	4.08	HbS carrier with alpha-thalassaemia (α3.7/αα).	[PDF]
563	Hb Camperdown	β	D-10	Dual Kit Program	46.7	0.68	Mildly unstable.	[PDF]
564	HbE	β	D-10	Dual Kit Program	41.2	2.78	Association of HbE and beta-thalassaemia.	[PDF]
568	HbC	β	D-10	Dual Kit Program	48.1	4.79	Compound heterozygote for HbC and Hb O-Arab.	[PDF]
569	Hb O-Arab	β	D-10	Dual Kit Program	41.6	4.56	Compound heterozygosity for HbC and Hb O Arab (extremely rare). This situation is important to be identified for genetic counselling since both alleles when associated to HbS lead to a severe sickle cell syndrome.	[PDF]
576	Hb Mexico	α1	D-10	Dual Kit Program	27.3	1.37	Heterozygous.	[PDF]
581	HbI	α1	D-10	Dual Kit Program	10.4	1.36	heterozygote	[PDF]
585	Hb Lepore-Boston-Washington	δ	D-10	Dual Kit Program	4.8	2.69	Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.	[PDF]
585	Hb Lepore-Boston-Washington	β	D-10	Dual Kit Program	4.8	2.69	Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.	[PDF]
589	Hb M-Milwaukee-2	β	D-10	Dual Kit Program	31.6	4.71	Congenital methemoglobinemia.	[PDF]
593	Hb Lepore-Boston-Washington	δ	D-10	Dual Kit Program	5.3	2.69	Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.	[PDF]
593	Hb Lepore-Boston-Washington	β	D-10	Dual Kit Program	5.3	2.69	Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.	[PDF]
599	Hb Aichi	α1 or α2	D-10	Dual Kit Program	21.9	4.05	Heterozygous. Elutes as HbS.	[PDF]
603	Hb Setif	α2	D-10	Dual Kit Program	3.5	1.43	Heterozygote. Elutes with HbA.	[PDF]
606	Hb Providence	β	D-10	Dual Kit Program	31.3	0.3	This variant is spontaneously deaminated X-Asn 13-19%; X-Asp 32-33% leading to several fast eluting peaks.	[PDF]
607	Hb Providence	β	D-10	Dual Kit Program	16.4	0.97	This variant is spontaneously deaminated X-Asn 13-19%; X-Asp 32-33% leading to several fast eluting peaks.	[PDF]
608	Hb Setif	α2	D-10	Dual Kit Program	11.3	4.4	Heterozygote.	[PDF]
4	Hb I-Interlaken	α1	VARIANT II	β-thal Short Program	24.8	1.63	Heterozygous	[PDF]
8	HbS	β	VARIANT II	β-thal Short Program	34.6	4.4	Heterozygous / Sickle Cell Trait	[PDF]
16	HbC	β	VARIANT II	β-thal Short Program	86.8	5.16	Compound heterozygous with CD 39. Could be confused with HbC homozygous. A2 level and hematological data suggest an associated beta-thal.	[PDF]
28	HbS	β	VARIANT II	β-thal Short Program	69.4	4.41	Compound heterozygote for HbS and HPFH	[PDF]
37	HbE	β	VARIANT II	β-thal Short Program	25.1	3.66	Heterozygous	[PDF]
56	Hb St. Claude	α1 or α2	VARIANT II	β-thal Short Program	22.4	1.88	Heterozygous. Clinically normal.	[PDF]
59	Hb G-Coushatta	β	VARIANT II	β-thal Short Program	75.1	3.48	Homozygous or associated with beta (0) thal.	[PDF]
62	Hb Camden	β	VARIANT II	β-thal Short Program	44.5	1.36	Clinically normal. Elutes near, or at the position of Hb A1c.	[PDF]
68	Hb Dhofar	β	VARIANT II	β-thal Short Program	12.8	3.92	Thalassemic Hb (in cis with a beta (+)-thalassemic mutation).	[PDF]
75	Hb Bicêtre	β	VARIANT II	β-thal Short Program	85.2	2.5	Unstable variant. Elutes with HbA.	[PDF]
79	Hb M-Saskatoon	β	VARIANT II	β-thal Short Program	11.7	5	Methemoglobinemia and unstable variant.	[PDF]
82	Hb Rainier	β	VARIANT II	β-thal Short Program	78.1	2.48	Increased oxygen affinity leading to erythrocytosis. Elutes as HbA.	[PDF]
83	Hb Rainier	β	VARIANT II	β-thal Short Program	78.3	2.51	Increased oxygen affinity leading to erythrocytosis. Elutes as a shoulder in the descending part of HbA	[PDF]
87	Hb J-Baltimore	β	VARIANT II	β-thal Short Program	44.8	1.83	Clinically normal.	[PDF]
91	Hb Acharnes	β	VARIANT II	β-thal Short Program	82.8	2.47	Unstable variant. Chronic hemolytic anemia. Elutes together with HbA0 or as a shoulder in the ascending part.	[PDF]
95	Hb Chad	α2	VARIANT II	β-thal Short Program	23.6	4.96	Heterozygous. Clinically normal.	[PDF]
99	Hb Roanne	α1 or α2	VARIANT II	β-thal Short Program	89.1	2.43	Heterozygote clinically normal. Elutes as HbA.	[PDF]
104	Hb Toulon	α2	VARIANT II	β-thal Short Program	25	3.57	Heterozygote clinically normal. Elutes in the HbA2 window.	[PDF]
107	Hb D-Ouled Rabah	β	VARIANT II	β-thal Short Program	75.1	3.57		[PDF]
111	Hb Lyon-Bron	α2	VARIANT II	β-thal Short Program	30.1	1.82	Heterozygous. Slightly decreased oxygen affinity, mild anaemia.	[PDF]
116	Hb Saint-Jacques	β	VARIANT II	β-thal Short Program	80.5	2.56	Heterozygous. Hb variant with increased oxygen affinity.	[PDF]
118	Hb Hamilton	β	VARIANT II	β-thal Short Program	87.4	2.55	Neutral variant, clinically normal. Elutes together with HbA on CE-HPLC. Abnormal chain could be observed by RP-HPLC. Diagnosis requires DNA studies.	[PDF]
122	Hb Gerland	α2	VARIANT II	β-thal Short Program	87.6	2.47
127	Hb Aubagne	β	VARIANT II	β-thal Short Program	86.2	2.55	Heterozygous. Unstable variant, mild hemolytic anaemia. Appears as a shoulder in the descending part of HbA0.	[PDF]
131	Hb Stanleyville-II	α2	VARIANT II	β-thal Short Program	29.7	4.31	Heterozygous. Clinically normal. Elutes as HbS.	[PDF]
135	Hb J-Sardegna	α2	VARIANT II	β-thal Short Program	30.3	1.24	Heterozygous. Elutes with HbF. DNA sequencing showed that the mutation leads to an Asn which is totally deamidated.	[PDF]
139	Hb Russ	α1	VARIANT II	β-thal Short Program	15.1	4.32	Heterozygous. Elutes in HbS window. Clinically normal.	[PDF]
143	Hb K Woolwich	β	VARIANT II	β-thal Short Program	34.4	1.29	Clinically and hematologically normal.	[PDF]
147	Hb Maputo	β	VARIANT II	β-thal Short Program	39.6	3.74	Clinically normal. Elutes as HbA2.	[PDF]
151	Hb Brem-sur-Mer	β	VARIANT II	β-thal Short Program	76.5	2.58	Clinically and hematologically normal. Elutes as HbA.	[PDF]
155	Hb Fannin-Lubbock II	β	VARIANT II	β-thal Short Program	36.1	1.91	This variant carries in addition to the mutation of Hb Fannin Lubbock [Gly>Asp] a second neutral mutation [beta Val>Leu] which modifies the retention time in RP-HPLC. Clinically normal.	[PDF]
163	Hb Malmö	β	VARIANT II	β-thal Short Program	18.3	1.7	High oxygen affinity variant, leads to erythrocytosis. Elutes together with HbA or before according to the chromatographic system used.	[PDF]
167	Hb Lombard	α2	VARIANT II	β-thal Short Program	88.8	2.55	Heterozygous. Elutes as a shoulder in the descending part of the HbA peak.	[PDF]
172	Hb J-Tongariki	α1 or α2	VARIANT II	β-thal Short Program	22.6	1.91	Heterozygous. Associated with alpha 3.7	[PDF]
176	Hb D-Iran	β	VARIANT II	β-thal Short Program	40.4	3.56	Carrier. Clinically normal. Elutes as HbA2 in CE-HPLC. Compound heterozygotes HbS/Hb D-Iran behave clinically as HbA/HbS.	[PDF]
180	Hb Yaounde	β	VARIANT II	β-thal Short Program	75.2	2.55	Clinically normal. Elutes as HbA.	[PDF]
184	Hb Dunn	α1 or α2	VARIANT II	β-thal Short Program	12.6	4.01	Heterozygote. Elutes in HbD window.	[PDF]
188	Hb J-Toronto	α1	VARIANT II	β-thal Short Program	22.4	1.88	Heterozygote. Clinically normal.	[PDF]
192	Hb Chicago	α2	VARIANT II	β-thal Short Program	85	2.5	Heterozygous. Elutes as HbA.	[PDF]
197	Hb Hikari	β	VARIANT II	β-thal Short Program	34.5	2.13	Clinically normal.	[PDF]
201	Hb G-Szuhu	β	VARIANT II	β-thal Short Program	34.5	2.13		[PDF]
205	Hb Ambroise Pare	α2	VARIANT II	β-thal Short Program	83.3	2.5	Heterozygous. Elutes with HbA.	[PDF]
209	Hb Groene Hart	α1	VARIANT II	β-thal Short Program	82.4	2.5	Mild non-deletional alpha thal variant. Migrates as HbA.	[PDF]
213	Hb Q-Thailand	α1	VARIANT II	β-thal Short Program	86.9	4.38	heterozygote	[PDF]
218	Hb Milledgeville	α2	VARIANT II	β-thal Short Program	22.3	2.26	Heterozygous. Increased oxygen affinity leading to a mild erythrocytosis.	[PDF]
222	Hb Nunobiki	α2	VARIANT II	β-thal Short Program	12.7	1.6	Heterozygous. Increased oxygen affinity leading to a mild erythrocytosis.	[PDF]
239	HbS	β	VARIANT II	β-thal Short Program	91.1	4.45	Sickle cell disease. The trace amount of HbA remains from a blood transfusion.	[PDF]
243	HbS	β	VARIANT II	β-thal Short Program	75.3	4.43	Homozygous HbS recently transfused.	[PDF]
249	HbS	β	VARIANT II	β-thal Short Program	25.3	4.43	HbS carrier with homozygous alpha + thalassemia.	[PDF]
252	HbS	β	VARIANT II	β-thal Short Program	79.8	4.47	Homozygous HbS. HbA remains from a blood transfusion.	[PDF]
256	Hb G-Philadelphia	α2	VARIANT II	β-thal Short Program	29	4.12	Heterozygous. Eluates as HbD. Associated with alpha thal.	[PDF]
260	HbC	β	VARIANT II	β-thal Short Program	25.1	5.11	Hb AC + alpha thal. The presence of an alpha thalassemia reduces the level of HbC and increases the microcytosis.	[PDF]
267	HbC	β	VARIANT II	β-thal Short Program	33.9	5.17	heterozygote	[PDF]
271	Hb D-Iran	β	VARIANT II	β-thal Short Program	38.7	3.54	Heterozygous. Elutes as HbA2 in CE-HPLC.	[PDF]
275	Hb Hasharon	α1	VARIANT II	β-thal Short Program	20	4.82	heterozygote	[PDF]
279	Hb Hopkins-II	α1	VARIANT II	β-thal Short Program	19	1.51	heterozygote	[PDF]
283	Hb J-Bangkok	β	VARIANT II	β-thal Short Program	38.7	1.92	heterozygote	[PDF]
287	Hb J-Broussais	α2	VARIANT II	β-thal Short Program	28.1	1.65	Heterozygote. Elutes near or with HbA1c.	[PDF]
291	Hb J-Paris-I	α1	VARIANT II	β-thal Short Program	26.2	1.71	heterozygote	[PDF]
295	Hb J-Sardegna	α2	VARIANT II	β-thal Short Program	34.3	1.19	Heterozygote. Elutes together with HbF.	[PDF]
299	Hb Le Lamentin	α2	VARIANT II	β-thal Short Program	25.6	1.49	heterozygote	[PDF]
303	Hb O-Arab	β	VARIANT II	β-thal Short Program	32.3	4.91	Heterozygote, clinically normal.	[PDF]
307	Hb O-Padova	α2	VARIANT II	β-thal Short Program	16.7	4.79	Heterozygote. Clinically normal.	[PDF]
311	Hb Q-India	α1	VARIANT II	β-thal Short Program	17.2	4.79	Heterozygote. Clinically normal.	[PDF]
315	HbS	β	VARIANT II	β-thal Short Program	36.9	4.43	HbS homozygote, transfused.	[PDF]
319	Hb D-Ibadan	β	VARIANT II	β-thal Short Program	39.1	3.94	Carrier. Clinically normal.	[PDF]
323	Hb Valletta	β	VARIANT II	β-thal Short Program	85.8	2.39	Heterozygous. Elutes with HbA. Clinically normal. This mutation is usually linked in cis to HbF Malta.	[PDF]
325	Hb F-Malta-I	Gγ	VARIANT II	β-thal Short Program	49.7	1.16	Heterozygous. Elutes near to HbF. Clinically normal. Associated in cis to Hb Valletta.	[PDF]
326	Hb F-Malta-I	Gγ	VARIANT II	β-thal Short Program	53.3	1.17	Heterozygous. Elutes near to HbF. Clinically normal. Associated in cis to Hb Valletta.	[PDF]
328	Hb St. Luke's	α1	VARIANT II	β-thal Short Program	9.4	4.46	Heterozygous. Elutes with HbS.	[PDF]
329	Hb St. Luke's	α1	VARIANT II	β-thal Short Program	8.8	4.58	Heterozygous. Elutes with HbS.	[PDF]
333	Hb Sunshine Seth	α2	VARIANT II	β-thal Short Program	16	4.79	heterozygote	[PDF]
337	HbE	β	VARIANT II	β-thal Short Program	69.5	3.64	Homozygote.	[PDF]
341	Hb Tacoma	β	VARIANT II	β-thal Short Program	71.4	2.41	Heterozygote carriers are clinically normal.	[PDF]
345	Hb Old Dominion/Burton-upon-Trent (OD/BuT)	β	VARIANT II	β-thal Short Program	33.2	1.88	heterozygote	[PDF]
349	Hb Hopkins-II	α1	VARIANT II	β-thal Short Program	10.3	1.6	Heterozygote.	[PDF]
353	Hb G-Philadelphia	α2	VARIANT II	β-thal Short Program	21.5	4.13	Heterozygous. Elutes as HbD. Associated with alpha thal.	[PDF]
355	Hb J-Bangkok	β	VARIANT II	β-thal Short Program	34.5	2.02	Clinically normal. Rare but found worldwide.	[PDF]
359	Hb Q-Iran	α2	VARIANT II	β-thal Short Program	21.2	4.85	heterozygote	[PDF]
363	HbC	β	VARIANT II	β-thal Short Program	18.5	4.86		[PDF]
367	Hb Le Lamentin	α2	VARIANT II	β-thal Short Program	5.6	1.66	heterozygote	[PDF]
371	Hb J-Meerut	α2	VARIANT II	β-thal Short Program	7.4	1.65	heterozygote	[PDF]
378	Hb Seal Rock	α2	VARIANT II	β-thal Short Program	0.9	4.77	Heterozygous. Modified C-terminal sequence.	[PDF]
382	Hb D-Punjab	β	VARIANT II	β-thal Short Program	37.3	4.14	heterozygote	[PDF]
386	Hb G-Accra	β	VARIANT II	β-thal Short Program	43.5	3.89	Normal in the heterozygote.	[PDF]
390	Hb Hope	β	VARIANT II	β-thal Short Program	47.8	1.4	In neonatal screening this Hb may be masked by the large amount of HbF and a baby compound heterozygous for HbS and Hb Hope may erroneously appear as an HbS homozygote.	[PDF]
394	Hb Austin	β	VARIANT II	β-thal Short Program	45.8	1.75	Normal in the heterozygote.	[PDF]
398	HbS	β	VARIANT II	β-thal Short Program	27.5	4.43	HbS carrier with alpha thalassemia (homoz. alpha 3.7).	[PDF]
402	HbS	β	VARIANT II	β-thal Short Program	31.9	4.44	HbS carrier + alpha-thal 2 (-3.7 del.).	[PDF]
407	Hb G-Copenhagen	β	VARIANT II	β-thal Short Program	39.2	3.75	Clinically normal. Elutes together with HbA2.	[PDF]
411	Hb G-San José	β	VARIANT II	β-thal Short Program	36.6	4.6	Clinically normal. Elutes in S Window.	[PDF]
415	HbC	β	VARIANT II	β-thal Short Program	85.4	5.13	Homozygote.	[PDF]
419	Hb Santa Clara	β	VARIANT II	β-thal Short Program	45.9	1.66	Heterozygote.	[PDF]
423	Hb D-Punjab	β	VARIANT II	β-thal Short Program	28.8	4.08	Heterozygous. Clinically normal in heterozygotes. Mild anemia in homozygotes.	[PDF]
427	Hb Hasharon	α1	VARIANT II	β-thal Short Program	27.1	4.82	Heterozygote with alpha 3.7. Clinically normal in heterozygote.	[PDF]
435	HbE	β	VARIANT II	β-thal Short Program	25.1	3.65	heterozygote	[PDF]
439	Hb Abruzzo	β	VARIANT II	β-thal Short Program	42	3.39	Hb with increased oxygen affinity.	[PDF]
443	Hb G-San José	β	VARIANT II	β-thal Short Program	33.3	4.6	Clinically normal. Elutes in S Window.	[PDF]
447	Hb Roma	β	VARIANT II	β-thal Short Program	3.33	4.6	Elutes with HbA.	[PDF]
450	Hb Camperdown	β	VARIANT II	β-thal Short Program	43.1	1.34	Hb variant is mildly unstable.	[PDF]
454	Hb Randwick	β	VARIANT II	β-thal Short Program	81.8	2.41	Elutes with HbA. Mildly unstable.	[PDF]
460	HbE	β	VARIANT II	β-thal Short Program	19.4	3.68	HbE heterozygote with alpha-thal 1 heterozygote.	[PDF]
464	HbE	β	VARIANT II	β-thal Short Program	27.1	3.68	Association of HbE and Hb Constant Spring	[PDF]
468	HbS	β	VARIANT II	β-thal Short Program	77.5	4.43	Heterozygote for Hb S/beta zero thal (Beta(0) CD39 (C/T)).	[PDF]
475	Hb Shelby	β	VARIANT II	β-thal Short Program	4.4	3.66	heterozygote	[PDF]
479	Hb D-Punjab	β	VARIANT II	β-thal Short Program	77.8	4.08	Double heterozygote Hb D-Punjab and beta-thalassaemia.	[PDF]
481	Hb Siirt	β	VARIANT II	β-thal Short Program	82.9	2.54	Elutes together with HbA.	[PDF]
484	Hb Valletta	β	VARIANT II	β-thal Short Program	66.1	2.65	Compound heterozygote with Hb Lepore. Elutes as HbA0.	[PDF]
495	Hb Randwick	β	VARIANT II	β-thal Short Program	66.8	2.66	Double heterozygote for Hb Randwick and beta-thalassaemia.	[PDF]
497	HbS	β	VARIANT II	β-thal Short Program	53.5	4.46	Hb S/beta thal (probably a delta-beta thalassemia).	[PDF]
501	HbS	β	VARIANT II	β-thal Short Program	11.8	4.36	Newborn homozygous for HbS. The peak eluting at the position of HbA2 may be aged HbS.	[PDF]
505	HbS	β	VARIANT II	β-thal Short Program	64.1	4.45	HbS homozygous with HPFH.	[PDF]
525	HbS	β	VARIANT II	β-thal Short Program	66	4.44	Compound heterozygote for HbS and B (+) thalassemia	[PDF]
531	HbS	β	VARIANT II	β-thal Short Program	45.9	4.45	Compound heterozygote for HbS and HbC	[PDF]
532	HbC	β	VARIANT II	β-thal Short Program	44.6	5.17	Compound heterozygote for HbS and HbC	[PDF]
538	Hb D-Punjab	β	VARIANT II	β-thal Short Program	41	4.06	Compound heterozygote for HbS and Hb D-Punjab.	[PDF]
539	HbS	β	VARIANT II	β-thal Short Program	37	4.42	Compound heterozygote for HbS and Hb D-Punjab.	[PDF]
544	HbC	β	VARIANT II	β-thal Short Program	60.5	5.15	Compound heterozygote for HbC and (delta-beta) zero thalassaemia.	[PDF]
548	HbC	β	VARIANT II	β-thal Short Program	61.8	5.16	Compound heterozygote for HbC and beta-thalassaemia.	[PDF]
550	Hb Gouda	α2	VARIANT II	β-thal Short Program	31.1	1.7	heterozygote	[PDF]
554	Hb A2' or Hb B2	δ	VARIANT II	β-thal Short Program	4.55	0.9	Homozygous.	[PDF]
557	Hb N-Baltimore	β	VARIANT II	β-thal Short Program	81.3	1.61	Hb N-Baltimore / Beta zero thalassaemia. Clinical normal.	[PDF]
561	HbS	β	VARIANT II	β-thal Short Program	32.5	4.46	HbS carrier + alpha-thal 2 (-3.7 deletion).	[PDF]
566	HbE	β	VARIANT II	β-thal Short Program	51.6	3.69	Association of HbE and beta-thalassaemia.	[PDF]
572	HbC	β	VARIANT II	β-thal Short Program	47.7	5.15	Compound heterozygote for HbC and Hb O-Arab.	[PDF]
573	Hb O-Arab	β	VARIANT II	β-thal Short Program	46.1	4.9	Compound heterozygosity for HbC and Hb O Arab (extremely rare). This situation is important to be identified for genetic counselling since both alleles when associated to HbS lead to a severe sickle cell syndrome.	[PDF]
578	Hb Mexico	α1	VARIANT II	β-thal Short Program	27.7	1.82	Heterozygous.	[PDF]
583	HbI	α1	VARIANT II	β-thal Short Program	14.9	1.4	heterozygote	[PDF]
587	Hb Lepore-Boston-Washington	δ	VARIANT II	β-thal Short Program	11.1	3.55	Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.	[PDF]
587	Hb Lepore-Boston-Washington	β	VARIANT II	β-thal Short Program	11.1	3.55	Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.	[PDF]
591	Hb M-Milwaukee-2	β	VARIANT II	β-thal Short Program	34.1	5.15	Congenital methemoglobinemia.	[PDF]
595	Hb Lepore-Boston-Washington	δ	VARIANT II	β-thal Short Program	10.8	3.5	Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.	[PDF]
595	Hb Lepore-Boston-Washington	β	VARIANT II	β-thal Short Program	10.8	3.5	Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.	[PDF]
597	HbI	α1	VARIANT II	β-thal Short Program	18.1	1.43	Heterozygote.	[PDF]
601	Hb Aichi	α1 or α2	VARIANT II	β-thal Short Program	21.1	4.33	Heterozygous. Elutes as HbS.	[PDF]
610	Hb Setif	α2	VARIANT II	β-thal Short Program	13.2	4.74	Heterozygote.	[PDF]
612	HbS	β	VARIANT II	β-thal Short Program	37.9	4.46	HbS carrier with Hb Montgomery (alpha variant).	[PDF]
613	Hb Montgomery	α2	VARIANT II	β-thal Short Program	6.3	4.98	Heterozygous. Association with HbS.	[PDF]
2	Hb I-Interlaken	α1	VARIANT	β-thal Short Program	24.9	1.62	Heterozygous	[PDF]
7	HbS	β	VARIANT	β-thal Short Program	34.5	4.26	Heterozygous / Sickle Cell Trait	[PDF]
15	HbC	β	VARIANT	β-thal Short Program	84.2	5.09	Compound heterozygous with CD 39. Could be confused with HbC homozygous. A2 level and hematological data suggest an associated beta-thal.	[PDF]
43	HbS	β	VARIANT	β-thal Short Program	77.2	4.3	Compoud heterozygote between HbS and beta (0) thal.	[PDF]
46	HbS	β	VARIANT	β-thal Short Program	22.9	4.35	HbS heterozygote with alpha thalassaemia (HbS + alpha-thal 2).	[PDF]
50	Hb Siirt	β	VARIANT	β-thal Short Program	82.3	2.5	Heterozygote clinically normal, the mild thalassemic syndrome observed may be in relation with the associated alpha gene abnormality (triple alpha). Hb Siirt elutes together with HbA.	[PDF]
67	Hb Dhofar	β	VARIANT	β-thal Short Program	13.9	3.84	Thalassemic Hb (in cis with a beta (+)-thalassemic mutation).	[PDF]
71	Hb Pierre-Bénite	β	VARIANT	β-thal Short Program	84.8	2.33	This variant displays a high oxygen affinity and leads to erythrocytosis. Elutes as HbA0.	[PDF]
74	Hb Bicêtre	β	VARIANT	β-thal Short Program	80.6	2.34	Unstable variant. Elutes with HbA.	[PDF]
78	Hb M-Saskatoon	β	VARIANT	β-thal Short Program	9.3	4.91	Methemoglobinemia and unstable variant.	[PDF]
86	Hb J-Baltimore	β	VARIANT	β-thal Short Program	40.8	1.8	Clinically normal.	[PDF]
90	Hb Acharnes	β	VARIANT	β-thal Short Program	30.2	2.28	Unstable variant. Chronic hemolytic anemia. Elutes together with HbA0 or as a shoulder in the ascending part.	[PDF]
94	Hb Chad	α2	VARIANT	β-thal Short Program	25.2	4.89	Heterozygous. Clinically normal.	[PDF]
98	Hb Roanne	α1 or α2	VARIANT	β-thal Short Program	88.5	2.48	Heterozygote clinically normal. Elutes as HbA.	[PDF]
103	Hb Toulon	α2	VARIANT	β-thal Short Program	23.9	3.52	Heterozygote clinically normal. Elutes in the HbA2 window.	[PDF]
106	Hb D-Ouled Rabah	β	VARIANT	β-thal Short Program	76.7	3.58		[PDF]
110	Hb Lyon-Bron	α2	VARIANT	β-thal Short Program	30.7	1.73	Heterozygous. Slightly decreased oxygen affinity, mild anaemia.	[PDF]
115	Hb Saint-Jacques	β	VARIANT	β-thal Short Program	79.2	2.5	Heterozygous. Hb variant with increased oxygen affinity.	[PDF]
121	Hb Gerland	α2	VARIANT	β-thal Short Program	85.7	2.46	Heterozygous. Elutes with HbA. Clinically asymptomatic neutral alpha chain variant.	[PDF]
124	Hb Henri Mondor	β	VARIANT	β-thal Short Program	35.7	2.92	Mild microcytic anaemia.	[PDF]
126	Hb Aubagne	β	VARIANT	β-thal Short Program	85.2	2.47	Heterozygous. Unstable variant, mild hemolytic anaemia. Appears as a shoulder in the descending part of HbA0.	[PDF]
130	Hb Stanleyville-II	α2	VARIANT	β-thal Short Program	29.9	4.18	Heterozygous. Clinically normal. Elutes as HbS.	[PDF]
134	Hb J-Sardegna	α2	VARIANT	β-thal Short Program	29.3	1.28	Heterozygous. Elutes with HbF. DNA sequencing showed that the mutation leads to an Asn which is totally deamidated.	[PDF]
138	Hb Russ	α1	VARIANT	β-thal Short Program	15.7	4.18	Heterozygous. Elutes in HbS window. Clinically normal.	[PDF]
142	Hb K Woolwich	β	VARIANT	β-thal Short Program	35.2	1.29	Clinically and hematologically normal.	[PDF]
146	Hb Maputo	β	VARIANT	β-thal Short Program	40.9	3.72	Clinically normal. Elutes as HbA2.	[PDF]
150	Hb Brem-sur-Mer	β	VARIANT	β-thal Short Program	72.1	2.4	Clinically and hematologically normal. Elutes as HbA.	[PDF]
154	Hb Fannin-Lubbock II	β	VARIANT	β-thal Short Program	36.5	1.82	This variant carries in addition to the mutation of Hb Fannin Lubbock [Gly>Asp] a second neutral mutation [beta Val>Leu] which modifies the retention time in RP-HPLC. Clinically normal.	[PDF]
158	Hb Passy	α2	VARIANT	β-thal Short Program	78.1	2.44	Heterozygous. Elutes with HbA. Unstable variant.	[PDF]
160	Hb Handsworth	α1	VARIANT	β-thal Short Program	0.7	4.7	Heterozygous. Clinically normal.	[PDF]
162	Hb Shimonoseki	α1	VARIANT	β-thal Short Program	14.5	4.21	Heterozygous. Elutes as HbS.	[PDF]
166	Hb Lombard	α2	VARIANT	β-thal Short Program	87	2.45	Heterozygous. Elutes with HbA.	[PDF]
171	Hb J-Tongariki	α1 or α2	VARIANT	β-thal Short Program	21.8	1.82	Heterozygous. Associated with alpha 3.7	[PDF]
175	Hb D-Iran	β	VARIANT	β-thal Short Program	40.3	3.55	Carrier. Clinically normal. Elutes as HbA2 in CE-HPLC. Compound heterozygotes HbS/Hb D-Iran behave clinically as HbA/HbS.	[PDF]
179	Hb Yaounde	β	VARIANT	β-thal Short Program	76.5	2.46	Clinically normal. Elutes as HbA.	[PDF]
183	Hb Dunn	α1 or α2	VARIANT	β-thal Short Program	13.2	3.95	Heterozygote. Elutes in HbD window.	[PDF]
187	Hb J-Tongariki	α1 or α2	VARIANT	β-thal Short Program	19.3	1.78	Heterozygous. Associated with alpha 3.7	[PDF]
191	Hb Chicago	α2	VARIANT	β-thal Short Program	84	2.47	Heterozygous. Elutes as HbA.	[PDF]
196	Hb Hikari	β	VARIANT	β-thal Short Program	35.3	2.04	Clinically normal.	[PDF]
200	Hb G-Szuhu	β	VARIANT	β-thal Short Program	37.7	4.54	Clinically normal.	[PDF]
204	Hb Ambroise Pare	α2	VARIANT	β-thal Short Program	81.5	2.44	Heterozygous. Elutes with HbA.	[PDF]
208	Hb Groene Hart	α1	VARIANT	β-thal Short Program	81.9	2.46	Mild non-deletional alpha thal variant. Migrates as HbA.	[PDF]
212	Hb Q-Thailand	α1	VARIANT	β-thal Short Program	22.9	4.51	heterozygote	[PDF]
215	Hb D-Punjab	β	VARIANT	β-thal Short Program	80.7	4.05	Clinically normal in heterozygotes. Mild anemia in homozygotes. Causes a severe sickle cell disease when associated to HbS.	[PDF]
217	Hb Milledgeville	α2	VARIANT	β-thal Short Program	18.4	2.19	Heterozygous. Increased oxygen affinity leading to a mild erythrocytosis.	[PDF]
221	Hb Nunobiki	α2	VARIANT	β-thal Short Program	12.8	1.51	Heterozygous. Increased oxygen affinity leading to a mild erythrocytosis.	[PDF]
225	Hb Summer Hill	β	VARIANT	β-thal Short Program	38.4	4.24	Heterozygote. Clinically normal. Elutes in HbS window.	[PDF]
227	Hb Fort de France	α1	VARIANT	β-thal Short Program	16.3	3.52	Heterozygote. Elutes in the window of HbA2.	[PDF]
229	Hb J-Broussais	α2	VARIANT	β-thal Short Program	24.8	1.62	Heterozygote. Elutes near or with HbA1c. Clinically normal.	[PDF]
231	HbS	β	VARIANT	β-thal Short Program	38.4	4.24	Homozygote. Classical chromatogram of an SS patient.	[PDF]
234	Hb K-Ibadan	β	VARIANT	β-thal Short Program	32	1.99	Heterozygote. Clinically normal.	[PDF]
238	HbS	β	VARIANT	β-thal Short Program	90.4	4.26	Sickle cell disease. The trace amount of HbA remains from a blood transfusion.	[PDF]
242	HbS	β	VARIANT	β-thal Short Program	74.5	4.26	Homozygous HbS recently transfused.	[PDF]
248	HbS	β	VARIANT	β-thal Short Program	22.4	4.25	HbS carrier with homozygous alpha + thalassemia.	[PDF]
255	Hb G-Philadelphia	α2	VARIANT	β-thal Short Program	26.7	4.01	Heterozygous. Eluates as HbD. Associated with alpha thal.	[PDF]
259	HbC	β	VARIANT	β-thal Short Program	23.8	5.03	Hb AC + alpha thal. The presence of an alpha thalassemia reduces the level of HbC and increases the microcytosis.	[PDF]
263	HbS	β	VARIANT	β-thal Short Program	80.8	4.38	Classical chromatogram of a SS patient, the high HbF level suggests that the patient may be heterozygote (or perhaps homozygote) for one of the haplotype stimulating HbF synthesis.	[PDF]
266	HbC	β	VARIANT	β-thal Short Program	37.6	4	heterozygote	[PDF]
270	Hb D-Iran	β	VARIANT	β-thal Short Program	38	3.56	Heterozygous. Elutes as HbA2 in CE-HPLC.	[PDF]
274	Hb Hasharon	α1	VARIANT	β-thal Short Program	19.5	4.74	heterozygote	[PDF]
278	Hb Hopkins-II	α1	VARIANT	β-thal Short Program	19.3	1.5	heterozygote	[PDF]
282	Hb J-Bangkok	β	VARIANT	β-thal Short Program	38.7	1.9	heterozygote	[PDF]
286	Hb J-Broussais	α2	VARIANT	β-thal Short Program	27.8	1.62	Heterozygote. Elutes near or with HbA1c.	[PDF]
290	Hb J-Paris-I	α1	VARIANT	β-thal Short Program	26.3	1.7	heterozygote	[PDF]
294	Hb J-Sardegna	α2	VARIANT	β-thal Short Program	34.8	1.18	Heterozygote. Elutes together with HbF.	[PDF]
298	Hb Le Lamentin	α2	VARIANT	β-thal Short Program	25.4	1.51	heterozygote	[PDF]
302	Hb O-Arab	β	VARIANT	β-thal Short Program	32.9	4.3	Heterozygote, clinically normal.	[PDF]
306	Hb O-Padova	α2	VARIANT	β-thal Short Program	15.3	4.73	Heterozygote. Clinically normal.	[PDF]
310	Hb Q-India	α1	VARIANT	β-thal Short Program	17.3	4.7	Heterozygote. Clinically normal.	[PDF]
314	HbS	β	VARIANT	β-thal Short Program	36.4	4.31	HbS homozygote, transfused.	[PDF]
318	Hb D-Ibadan	β	VARIANT	β-thal Short Program	39.1	3.85	Carrier. Clinically normal.	[PDF]
322	Hb Valletta	β	VARIANT	β-thal Short Program	87	2.46	Heterozygous. Elutes with HbA. Clinically normal. This mutation is usually linked in cis to HbF Malta.	[PDF]
332	Hb Sunshine Seth	α2	VARIANT	β-thal Short Program	18.8	4.71	heterozygote	[PDF]
336	HbE	β	VARIANT	β-thal Short Program	76.4	3.65	Homozygote.	[PDF]
340	Hb Tacoma	β	VARIANT	β-thal Short Program	72.1	2.41	Heterozygote carriers are clinically normal.	[PDF]
344	Hb Old Dominion/Burton-upon-Trent (OD/BuT)	β	VARIANT	β-thal Short Program	32.6	1.85	heterozygote	[PDF]
348	Hb Hopkins-II	α1	VARIANT	β-thal Short Program	12.5	1.46	Heterozygote.	[PDF]
352	Hb G-Philadelphia	α2	VARIANT	β-thal Short Program	21.7	4.04	Heterozygous. Associated with alpha thal.	[PDF]
358	Hb Gouda	α2	VARIANT	β-thal Short Program	30.9	1.64	Heterozygote. Clinically normal.	[PDF]
362	HbC	β	VARIANT	β-thal Short Program	79.4	5.06	HbC homozygous or compound heterozygous with beta zero thalassaemia.	[PDF]
366	Hb Le Lamentin	α2	VARIANT	β-thal Short Program	33	1.49	heterozygote	[PDF]
370	Hb J-Meerut	α2	VARIANT	β-thal Short Program	17.6	1.86	heterozygote	[PDF]
374	Hb Winnipeg	α1	VARIANT	β-thal Short Program	18	4.74	Heterozygote.	[PDF]
377	Hb Seal Rock	α2	VARIANT	β-thal Short Program	1.9	4.7	Heterozygous. Modified C-terminal sequence.	[PDF]
381	Hb D-Punjab	β	VARIANT	β-thal Short Program	37.4	4.08	heterozygote	[PDF]
385	Hb G-Accra	β	VARIANT	β-thal Short Program	43.9	3.88	Normal in the heterozygote.	[PDF]
389	Hb Hope	β	VARIANT	β-thal Short Program	47.3	1.36	In neonatal screening this Hb may be masked by the large amount of HbF and a baby compound heterozygous for HbS and Hb Hope may erroneously appear as an HbS homozygote.	[PDF]
393	Hb Austin	β	VARIANT	β-thal Short Program	45.6	1.64	Normal in the heterozygote.	[PDF]
397	HbS	β	VARIANT	β-thal Short Program	28.2	4.3	HbS carrier with alpha thalassemia (homoz. alpha 3.7).	[PDF]
401	HbS	β	VARIANT	β-thal Short Program	32	4.33	HbS carrier + alpha-thal 2 (-3.7 del.).	[PDF]
404	Hb N-Baltimore	β	VARIANT	β-thal Short Program	83.7	1.65		[PDF]
406	Hb G-Copenhagen	β	VARIANT	β-thal Short Program	40.6	3.74	Clinically normal. Elutes together with HbA2.	[PDF]
410	Hb G-San José	β	VARIANT	β-thal Short Program	34.5	4.54	Clinically normal.	[PDF]
414	HbC	β	VARIANT	β-thal Short Program	82.3	5.06	Homozygote.	[PDF]
418	Hb Santa Clara	β	VARIANT	β-thal Short Program	46.7	1.65	Heterozygote.	[PDF]
422	Hb D-Punjab	β	VARIANT	β-thal Short Program	28	3.99	Heterozygous. Clinically normal in heterozygotes. Mild anemia in homozygotes.	[PDF]
426	Hb Hasharon	α1	VARIANT	β-thal Short Program	25.7	4.74	Heterozygote with alpha 3.7. Clinically normal in heterozygote.	[PDF]
430	Hb Hasharon	α1	VARIANT	β-thal Short Program	27.9	4.74	Heterozygote with alpha 3.7. Clinically normal in heterozygote.	[PDF]
434	HbE	β	VARIANT	β-thal Short Program	25	3.63	heterozygote	[PDF]
442	Hb G-San José	β	VARIANT	β-thal Short Program	31.3	4.52	Clinically normal.	[PDF]
446	Hb Roma	β	VARIANT	β-thal Short Program	31.3	4.52	Elutes with HbA.	[PDF]
449	Hb Camperdown	β	VARIANT	β-thal Short Program	45.9	1.29	Hb variant is mildly unstable.	[PDF]
453	Hb Randwick	β	VARIANT	β-thal Short Program	82.6	2.38	Elutes with HbA. Mildly unstable.	[PDF]
459	HbE	β	VARIANT	β-thal Short Program	17.7	3.64	HbE heterozygote with alpha-thal 1 heterozygote.	[PDF]
463	HbE	β	VARIANT	β-thal Short Program	25.3	3.68	Association of HbE and Hb Constant Spring	[PDF]
471	Hb Shelby	β	VARIANT	β-thal Short Program	10.6	3.61	Compound heterozygous Hb Shelby / Beta zero Thalassemia.	[PDF]
474	Hb Shelby	β	VARIANT	β-thal Short Program	3.9	3.62	heterozygote	[PDF]
478	Hb D-Punjab	β	VARIANT	β-thal Short Program	73.7	4.01	Double heterozygote Hb D-Punjab and beta-thalassaemia.	[PDF]
483	Hb Valletta	β	VARIANT	β-thal Short Program	66.4	2.58	Compound heterozygote with Hb Lepore. Elutes as HbA0.	[PDF]
489	HbC	β	VARIANT	β-thal Short Program	32	5.1	compound heterozygote for HbC and Hb Korle Bu	[PDF]
491	HbS	β	VARIANT	β-thal Short Program	31.4	4.37	compound heterozygote for HbC and HbS	[PDF]
492	HbC	β	VARIANT	β-thal Short Program	29.9	5.11	Compound heterozygote for HbC and HbS. Recently transfused.	[PDF]
494	Hb Randwick	β	VARIANT	β-thal Short Program	67.7	2.64	Double heterozygote for Hb Randwick and beta-thalassaemia.	[PDF]
500	HbS	β	VARIANT	β-thal Short Program	12	4.22	Newborn homozygous for HbS. The peak eluting at the position of HbA2 may be aged HbS.	[PDF]
504	HbS	β	VARIANT	β-thal Short Program	62.8	4.26	HbS homozygous with HPFH.	[PDF]
507	HbS	β	VARIANT	β-thal Short Program	79.7	4.37	Homozygous HbS. HbA remains from a blood transfusion.	[PDF]
510	HbS	β	VARIANT	β-thal Short Program	45.1	4.35	Compound heterozygote for HbS and HbC	[PDF]
511	HbC	β	VARIANT	β-thal Short Program	45.8	5.1	Compound heterozygote for HbC and HbS	[PDF]
515	HbS	β	VARIANT	β-thal Short Program	74.6	4.38	Compound heterozygote for HbS and Beta (+) thal	[PDF]
519	HbS	β	VARIANT	β-thal Short Program	45.8	4.37	Compound heterozygote for HbS and HbC	[PDF]
524	HbS	β	VARIANT	β-thal Short Program	64.2	4.32	Compound heterozygote for HbS and B (+) thalassemia	[PDF]
529	HbS	β	VARIANT	β-thal Short Program	44.7	4.36	Compound heterozygote for HbS and HbC	[PDF]
530	HbC	β	VARIANT	β-thal Short Program	45.9	5.11	Compound heterozygote for HbS and HbC	[PDF]
536	Hb D-Punjab	β	VARIANT	β-thal Short Program	40.7	4	Compound heterozygote for HbS and Hb D-Punjab.	[PDF]
537	HbS	β	VARIANT	β-thal Short Program	40.2	4.3	Compound heterozygote for HbS and Hb D-Punjab	[PDF]
543	HbC	β	VARIANT	β-thal Short Program	61.1	5.1	Compound heterozygote for HbC and (delta-beta) zero thalassaemia.	[PDF]
547	HbC	β	VARIANT	β-thal Short Program	62	5.1	Compound heterozygote for HbC and beta-thalassaemia.	[PDF]
553	Hb A2' or Hb B2	δ	VARIANT	β-thal Short Program	1.5	4.47		[PDF]
560	HbS	β	VARIANT	β-thal Short Program	31.6	4.35	HbS carrier + alpha-thal 2 (-3.7 deletion).	[PDF]
565	HbE	β	VARIANT	β-thal Short Program	47	3.73	Association of HbE and beta-thalassaemia.	[PDF]
570	HbC	β	VARIANT	β-thal Short Program	47.7	5.12	Compound heterozygote for HbC and Hb O-Arab.	[PDF]
571	Hb O-Arab	β	VARIANT	β-thal Short Program	44.8	4.85	Compound heterozygosity for HbC and Hb O Arab (extremely rare). This situation is important to be identified for genetic counselling since both alleles when associated to HbS lead to a severe sickle cell syndrome.	[PDF]
577	Hb Mexico	α1	VARIANT	β-thal Short Program	27.8	1.75	Heterozygous.	[PDF]
582	HbI	α1	VARIANT	β-thal Short Program	14.8	1.39	heterozygote	[PDF]
586	Hb Lepore-Boston-Washington	δ	VARIANT	β-thal Short Program	10.5	3.5	Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.	[PDF]
586	Hb Lepore-Boston-Washington	β	VARIANT	β-thal Short Program	10.5	3.5	Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.	[PDF]
590	Hb M-Milwaukee-2	β	VARIANT	β-thal Short Program	34.9	5.08	Congenital methemoglobinemia.	[PDF]
594	Hb Lepore-Boston-Washington	δ	VARIANT	β-thal Short Program	9.7	3.42	Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.	[PDF]
594	Hb Lepore-Boston-Washington	β	VARIANT	β-thal Short Program	9.7	3.42	Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.	[PDF]
600	Hb Aichi	α1 or α2	VARIANT	β-thal Short Program	19.7	4.17	Heterozygous. Elutes as HbS.	[PDF]
604	Hb Setif	α2	VARIANT	β-thal Short Program	3.5	1.6	Heterozygote. Elutes with HbA.	[PDF]
609	Hb Setif	α2	VARIANT	β-thal Short Program	14.5	4.66	Heterozygote.	[PDF]
40	HbC	β	VARIANT II	Dual Kit Program - HbA1c	41.7	2.04	heterozygote	[PDF]
41	Hb D-Punjab	β	VARIANT II	Dual Kit Program - HbA1c	42.2	1.83	Heterozygous; Clinically normal in heterozygotes. Mild anemia in homozygotes. Causes a severe sickle cell disease when associated to HbS.	[PDF]
42	HbS	β	VARIANT II	Dual Kit Program - HbA1c	44.7	1.88	Heterozygous / Sickle Cell Trait	[PDF]
64	HbE	β	VARIANT II	Dual Kit Program - HbA1c	85.9	1.737	homozygote	[PDF]
456	HbS	β	VARIANT II	Dual Kit Program - HbA1c	44.9	2.035	Compound heterozygote between HbS and HbC	[PDF]
457	HbS	β	VARIANT II	Dual Kit Program - HbA1c	85.6	1.87	Classic chromatogram of an SS patient.	[PDF]
11	HbS	β	VARIANT II	HbA1c Program	39.2	1.94	Sickle Cell Trait	[PDF]
13	HbS	β	VARIANT II	HbA1c Program	84.4	1.93	Homozygous	[PDF]
19	HbE	β	VARIANT II	HbA1c Program	30.3	1.86	Heterozygous	[PDF]
21	HbE	β	VARIANT II	HbA1c Program	80.1	1.84	Homozygous	[PDF]
23	Hb D-Punjab	β	VARIANT II	HbA1c Program	40	1.9	Heterozygous; Clinically normal in heterozygotes. Mild anemia in homozygotes. Causes a severe sickle cell disease when associated to HbS.	[PDF]
25	Hb O-Arab	β	VARIANT II	HbA1c Program	31.3	2.02	Heterozygous; Heterozygote clinically normal. Homozygote present with a mild microcytic anemia. When associated to HbS leads to a severe sickle cell anemia.	[PDF]
29	HbS	β	VARIANT II	HbA1c Program	39.2	1.94	Heterozygote / Sickle Cell Trait	[PDF]
31	Hb D-Punjab	β	VARIANT II	HbA1c Program	40	1.9	Heterozygote; Heterozygous; Clinically normal in heterozygotes. Mild anemia in homozygotes. Causes a severe sickle cell disease when associated to HbS.	[PDF]
33	HbC	β	VARIANT II	HbA1c Program	37.1	2.11	Heterozygote	[PDF]
35	HbC	β	VARIANT II	HbA1c Program	97	2.1	Homozygote; HbC homozygote does not lead to a thal intermedia but to a mild microcytic anemia.	[PDF]
466	HbS	β	VARIANT II	HbA1c Program	52.1	1.94	Compound heterozygote between HbS and HbC	[PDF]
10	HbS	β	D-10	HbA1c Program	40	1.65	Heterozygous / Sickle Cell Trait	[PDF]
12	HbS	β	D-10	HbA1c Program	81.2	1.65	Homozygous	[PDF]
18	HbE	β	D-10	HbA1c Program	31.4	1.59	Heterozygous	[PDF]
20	HbE	β	D-10	HbA1c Program	80.8	1.58	Homozygous	[PDF]
22	Hb D-Punjab	β	D-10	HbA1c Program	41.5	1.63	Heterozygous; Clinically normal in heterozygotes. Mild anemia in homozygotes. Causes a severe sickle cell disease when associated to HbS.	[PDF]
24	Hb O-Arab	β	D-10	HbA1c Program	64.9	1.49	Heterozygous; Heterozygote clinically normal. Homozygote present with a mild microcytic anemia. When associated to HbS leads to a severe sickle cell anemia.	[PDF]
30	Hb D-Punjab	β	D-10	HbA1c Program	41.5	1.63	Heterozygous; Clinically normal in heterozygotes. Mild anemia in homozygotes. Causes a severe sickle cell disease when associated to HbS.	[PDF]
32	HbC	β	D-10	HbA1c Program	46.5	1.77	Heterozygote	[PDF]
34	HbC	β	D-10	HbA1c Program	89	1.76	Homozygote; HbC homozygote does not lead to a thal intermedia but to a mild microcytic anemia.	[PDF]
36	HbS	β	D-10	HbA1c Program	38.2	1.77	Compound heterozygote between HbS and HbC	[PDF]

Please Contact Us to provide new HPLC data and/or report mistakes.

IthaChrom Curators: Celeste Bento, Petros Kountouris, Coralea Stephanou

Disclaimer: The HPLC images are provided by Bio-Rad Laboratories, Inc as an information resource only. Bio-Rad Laboratories, Inc and the ITHANET Portal disclaim responsibility and have no liability if this information is used for diagnostic or treatment purposes. D-10™ and VARIANT™ are registered trademarks of Bio-Rad Laboratories, Inc. and used with permission. Redistribution and use of the above material is allowed only with permission by Bio-Rad Laboratories, Inc.